Budesonide controlled-release - Cosmo Pharmaceuticals

Drug Profile

Budesonide controlled-release - Cosmo Pharmaceuticals

Alternative Names: Budesonide controlled release; Budesonide CR; Budesonide MMX®; budesonide multimatrix; Cortiment; Cortiment MMX; Uceris oral

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Ferring Pharmaceuticals; Salix Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis

Most Recent Events

  • 31 Oct 2017 The United States District Court for the District of Delaware dismisses patent litigation filed against Teva for ANDA application of budesonide controlled-release
  • 28 Jul 2016 Launched for Ulcerative colitis in Canada (PO)
  • 20 Jun 2016 Registered for Ulcerative colitis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top